Advanced Immune Therapeutic strategies (ait strategies) is a privately held firm focusing on biomedical research and development with a special interest in immunotherapeutics.
AIT Strategies believes that the immune system in individuals has the capacity to detect and eliminate cancer; however, in most clinical presentations, this capacity has proven to be immobilized or is by-passed by factors induced by the malignancy.
Our goal is to facilitate development of novel cancer therapeutics and synergistic combinations that enhance specific immunity for the potential benefit of all those touched by cancer. It is becoming widely accepted that combination therapies will be necessary to successfully mobilize the immunotherapeutic treatment of cancer and to maintain immune responses induced by cancer immunotherapies.
We work with multiple technology platforms designed to stimulate specific immunity including monoclonal antibodies, adjuvant and vaccine approaches. We collaborate with academic researchers and other immunology or cancer therapy companies. Several main areas of focus are noted:
- Therapeutic IgE for Cancer. From the original development at Advanced Immune Therapeutics this technology has been further developed at Quest PharmaTech in collaboration with multiple academic investigators. AIT Strategies continues to champion progress in this field and is excited by the opportunity to continue this work with OncoQuest, Inc. the new oncology subsidiary of Quest PharmaTech and with OncoVent, a Joint Venture established with Shenzhen Hepalink to create the next step forward in this exciting new area of cancer research.
- Therapeutic IgG for Cancer. Specific IgG when dosed in the appropriate immunogenic range is an effective method to induce a cellular immunity. AIT Strategies and collaborators have worked extensively studying this use of a monoclonal antibody as a cancer treatment approach. This technology has been advanced most recently by Quest PharmaTech and has also been placed into the new Immuno-Oncology portfolio of OncoQuest, Inc. where monoclonal antibodies to CA125 (MUC16) and MUC-1 are being advanced with the intention of establishing improved treatments for ovarian, pancreatic, colon and other tumors expressing these tumor markers. Progress with checkpoint inhibition has recently opened new opportunities for allowing induced specific immunity to overcome tumor derived immune suppression and control disease. AIT Strategies believes tailored combinatorial strategies will succeed where previous efforts with monotherapies were unable to overcome immune resistance. Efforts focus on schedule dependent combination wtih chemotherapy in newly diagnosed disease and combination with checkpoint inhibitors and TLR agonists in advanced disease.
- Use of Selective Adjuvants. AIT Strategies is collaborating with industrial partners to identify promising and clinically practical agents that have the potential to meaningfully enhance therapeutic outcomes of cancer specific immunotherapy. Several publications in this area reflect this effort.
- Clinical Development Services. AIT Strategies has expertise in the pathobiology of human disease, preclinical and clinical development of novel therapeutics. We provide fee for service support to select clients in a variety of disciplines, notably medical and data monitoring, clinical safety, operational planning and regulatory strategy.